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Digital breast tomosynthesis is an advancement of mammography, and has the potential to overcome limitations 
of standard digital mammography (DM). This randomized, controlled clinical trial (RCT) with a parallel group 
design aimed to investigate the potential superiority of first generation digital breast tomosynthesis including 2D 
synthetic mammograms (DBT) versus DM in an organized population-based screening program.  
 
Methods  
BreastScreen Norway offers all women aged 50-69, two view (craniocaudal and medio-lateral-oblique) 
mammographic screening every two years and performs independent double reading with consensus. We asked 
all 32,976 women who attended the program in Bergen in 2016-2017 to participate in this trial. A study-specific 
software was developed to allocate women to either DBT or DM using a 1:1 simple randomization method based 
on participants’ unique national identity numbers. The interviewing radiographer performed the randomization 
by entering the number into the software. Randomization was performed after consent and was therefore 
concealed from both the women and the radiographer at the time of consent; the algorithm was not disclosed to 
radiographers during the study period. All data needed for analyses were complete 12 months after the 
recruitment period ended. The primary outcome measure was screen-detected breast cancer, stratified by 
screening technique (DBT and DM). A log-binomial regression model was used to estimate the efficacy of DBT 
versus DM, defined as the crude risk ratios (RR) with 95% confidence intervals (CI) for screen-detected breast 
cancer for women screened during the recruitment period. A per protocol approach was used in the analyses. 
This RCT is registered at ClinicalTrials.gov (NCT02835625). 
Findings  
During the recruitment period, Jan 14, 2016 and Dec 31, 2017, 44,266 women were invited to the screening 
program in Bergen, and 32,976 (74.5%) attended. After excluding women with breast implants and those who 
did not consent to participate, 29,453 were eligible for electronic randomization. The randomization allocated 
14,734 women to DBT and 14,719 to DM. Post-randomization, we excluded women with a prior breast cancer 
(DBT: n=314, DM: n=316), women with metastases from melanoma (DBT: n=1, DM: n=0), and those who 
informed the radiographer about breast symptoms after providing consent (DBT: n=39, DM: n=34). After 
exclusions, information from 28,749 consenting women were included in the analyses; 14,380 in the DBT arm 
and 14,369 in the DM arm.  
The rate of screen-detected breast cancer among the screened women did not differ statistically between DBT 
and DM (0.66% (95/14,380) versus 0.61% (87/14,369), p=0.56). The RR of screen-detected breast cancer 
(RR=1.09, 95% CI: 0.82-1.46, p=0.56) did not differ statistically between the two arms.  
Interpretation 
This RCT indicated that DBT including synthetic 2D mammograms was as good of a screening tool as standard 
DM for detection of breast cancer in a population based screening program. Economic analyses and follow-up 
studies on interval and consecutive round screen-detected breast cancers are needed to better understand the 
effect of DBT in population-based breast cancer screening. 
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Standard digital mammography (DM) in combination with digital breast tomosynthesis (DBT) has been shown 
to increase the rate of screen-detected breast cancer, but its effect on recall varied in a meta-analysis of non-
randomized studies (1). These studies included women of different ages, with varying screening intervals, and 
with a variety of screening and reading procedures (2-5). Two study designs were generally used to compare the 
outcome of screening with DBT+DM versus DM alone: Paired studies using women as their own controls (2-5), 
and unpaired studies using other geographical areas or historical data as a control group (6-9). The paired studies 
demonstrated a consistent increase in the detection of breast cancer, but the design hampers future analyses of 
interval and consecutive breast cancer. The unpaired studies demonstrated a less convincing increase in cancer 
detection, and the sample sizes varied considerably (1). To our knowledge, results from only one randomized 
controlled clinical trial (RCT) comparing DBT+DM versus DM have been published in an interim report (10). 
This study showed a 90% higher rate of screen-detected breast cancer for women screened with DBT+DM 
versus DM alone.  
Lower recall rates for DBT+DM have been demonstrated, but mostly in studies from the U.S., where recall rates 
are known to be substantially higher than in Europe (1). A lower recall rate is beneficial for women if the rate of 
screen-detected breast cancer remains stable or increases. However, a higher rate of screen-detected breast 
cancer is only beneficial for screened women if the tumors are progressive, as opposed to small, low 
histologically graded tumors, which might represent overdiagnosis. If screen-detected breast cancers are detected 
at an earlier stage, we expect the rate of interval and/or consecutive screen-detected breast cancer to decrease as 
a result.  
The use of DBT+DM roughly doubles the radiation dose compared to DM alone (11). As a result, synthetic 2D 
mammograms (SM) has been developed using raw-data from the DBT acquisition to minimize the radiation 
burden on women. As far as we are aware, there is insufficient evidence to draw any conclusions about the 
overall balance of benefits and harms of using DBT+SM in a population-based screening program, and no results 
from RCTs are available (11-13).   
To fill the evidence gaps in the use of DBT in combination with SM in breast cancer screening, we performed a 
RCT in BreastScreen Norway – the Tomosynthesis trial in Bergen (the To-Be trial). This trial aimed to 
investigate performance measures and economic aspects of using DBT+SM (hereafter referred to as DBT) 
versus DM alone in an organized, population-based breast cancer screening program with a high attendance rate 
and complete follow-up data (14). This article presents results of outcome measures for women screened with 
DBT versus DM regarding the screen-detected breast cancer, consensus, recall, and distribution of 
histopathologic tumor characteristics, in addition to the positive predictive value of recall (PPV-1) and biopsy 




Study design and participants  
The To-Be trial was designed as a large-scale parallel group RCT where the outcome of the novel screening 
technique DBT was tested in an everyday screening setting. Participants were screened in Bergen through the 
national screening program, BreastScreen Norway, between Jan 15, 2016 and Dec 31, 2017 (recruitment period). 
BreastScreen Norway offers women aged 50-69 years biennial two-view mammographic screening (14). The 
Cancer Registry of Norway administers the program. Cancer registration is mandated by law in Norway, and the 
Registry’s databases are >99% complete for breast cancer. This provided a unique opportunity to link the trial 
data with registry data on individual screening episodes, including any follow-up and diagnosis performed as a 
part of, or outside, BreastScreen Norway.  
A total of 44,266 women born between 1947 and 1966 were invited to the screening unit in Bergen during the 
recruitment period (Figure 1). All attending women (n=32,976, 74.5%) were informed about the trial and 
received written information from an administrative assistant when they entered the screening unit. In the pre-
screening room, radiographers prepared women for the screening exam and asked about participation in the trial 
before they asked general questions, following standard procedures. Those who agreed to participate signed an 
electronic consent.  
The To-Be trial was approved by the Regional Committees for Medical and Health Research Ethics in South 
Eastern Norway (official record number 2015/424), and registered at ClinicalTrials.gov (NCT02835625). 
 
Randomization and masking 
We developed a study-specific software to randomly allocate women to receive either DBT or DM using a 1:1 
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simple randomization method based on participants’ unique 11-digit national identity numbers. This number 
sequence includes two randomly generated control digits, one of which was used by the randomization software 
to assign the screening technique. The interviewing radiographer in the pre-screening room performed the 
randomization by entering the unique identification number of the consenting women into the software. 
Randomization was done after consent was obtained and was therefore concealed from both the women and the 
radiographer at the time of consent. Only the PI and the software developers knew the algorithm for 
randomization; it was concealed to the radiographers during the study period. We evaluated the randomization 
process continuously, but did not evaluate the masking of the trial arm allocation. Due to the characteristics of 
the intervention, it was not possible to blind the intervention neither in the screening nor in the reading process.   
Attendance rates in the program and the trial were accessible for all professionals involved throughout the 
duration of the study. No other results were made available during the recruitment period. Quality control and 
assurance was continuously performed according to standard procedures, as interim analyses, to ensure the 
women’s safety according to radiation dose, recall and breast cancer detection, and for continuation of the trial. 
In the case of unacceptable values, the trial would have been discontinued. Results were regularly presented for 




Consenting women underwent one screening examination during the recruitment period. A standard examination 
consisted of two-view (craniocaudal and mediolateral oblique views) mammography of each breast, either with 
DBT including SM or DM, using imaging equipment from GE Health Care (SenoClaire 3D Breast 
Tomosynthesis™). Two radiographers performed the screening examination as a team and all examinations took 
place at one of the two equally equipped examination rooms. The DBT acquisition consisted of nine exposures 
over an angle of 25°, reconstructed into SM, 10mm slabs, and 1mm planes. Mean glandular dose per exam was 
2.96 mGy for DBT and 2.95 mGy for DM during the first year of the trial (15). Independent double reading was 
performed on IDI workstations, each with two 5-megapixel monitors (GE Healthcare MammoWorkstation 
Version 4.7.0 Image Diagnost).  
A standardized reading protocol including two-view SM, slabs and planes of each breast for DBT or two-view 
DM of each breast, was used for screen reading (Appendix A) and at the consensus meetings (hereafter referred 
as consensus). Up to four prior screening examinations, and/or diagnostic images from the previous ten years 
were available on the workstation for both trial arms, both for screen reading and at consensus.  
We performed independent double-reading with consensus, following the program’s standard procedures (14). 
Each breast was assigned a score of 1-5 from each radiologist. A score of 1 indicated the screening examination 
was negative for abnormality; 2, probably benign; 3, intermediate suspicion; 4, probably malignant; and 5, high 
suspicion of malignancy. If either radiologist assigned a score of 2 or higher, consensus was used to determine 
whether to recall the woman for further assessment, hereafter referred to as recall. Consensus was performed by 
pairs of radiologists, and a third radiologist was consulted if the pair could not agree. 
A pool of eight breast radiologists performed the initial screen readings and consensuses. Their experience in 
screen reading (screen-film and DM) prior to start-up of the RCT varied from zero to roughly 110,000 
examinations (15). The number of DBT and DM screen readings, and interpretation time in the trial were 
automatically recorded for each radiologist, while the consensus time was recorded for each meeting. 
Further assessment took place 2-8 weeks after screening, at the breast center at Haukeland University Hospital 
by the same pool of radiologists who did the screen reading. If indicated, additional imaging, including DBT, 
ultrasound, and less frequently contrast enhanced spectral mammography, and/or MRI, was performed. Cancer 
diagnoses were verified by pathologists examining histological specimens. Information about histopathologic 
features were considered complete 12 months after further assessment took place. 
Women were the unit of analysis and since all women were screened only once in the trial, the number of 
women and screening examinations were the same. Women with bilateral breast cancer were included once 
based on the topography of the recalled lesion or, if recalled for lesions in both breasts, based on malignancy 
according to histologic type (invasive before ductal carcinoma in situ, DCIS), tumor diameter and histologic 
grade. Histopathologic tumor characteristics for DCIS and invasive breast cancer were deteremined from routine 
histopathology reports performed by pathologists affiliated with the breast center at Haukeland University 
Hospital, with no reclassification. Lobular carcinoma in situ (LCIS) was included in the group of benign lesions 
(n=3 for DBT and n=2 for DM) (16). We diagnosed one case of pleomorphic lobular carcinoma in situ in the 




We collected information about the screening examinations and screen reading electronically, in compliance 
with standard procedures at BreastScreen Norway. Additional information related to consensus and recall was 
manually recorded on a paperbased form, which was designed specifically for this trial by the PI and the 
radiologists at the breast center. These forms were transferred electronically or by letter mail to the Cancer 
Registry of Norway, where the data were registered and quality assured by a dedicated research assistant before 
interim and final analyses were performed. All study data were stored in databases at the Cancer Registry.  
Outcomes  
The main objective of this RCT was to determine whether the rate of screen-detected breast cancer was favorable 
for DBT versus DM, as pre-specified in the protocol. Breast cancer was defined as histologically verified DCIS 
and/or invasive breast cancer. 
 
Secondary outcome measures, also specified in the protocol, were recalls, positive predictive value of recall 
(PPV-1) and biopsy (PPV-2), histopathologic tumor characteristics, and economic aspects. PPV-1 was the 
percentage of breast cancer cases detected among those recalled and PPV-2 the percentage of breast cancer 
detected among recalled women who underwent a needle biopsy.  
 
Prognostic characteristics for invasive tumors included mean and median tumor diameter, and distribution of 
tumor diameter groups (<10 mm, 10-<20 mm and ≥20 mm), histologic grade (1, 2 and 3), and lymph node 
involvement (negative/positive) were presented as percentages of all values. For tumor diameter, lesions treated 
with neoadjuvant therapy were included in the category “information not available” in the respective tables (n=9 
for DBT and n=11 for DM). Predictive biomarkers included estrogen and progesterone receptor status (ER+/- 
and PR +/-), human epidermal growth factor 2 receptor status (Her2 +/-), and Ki67 proliferation (<30% and 
≥30%). This information was used to classify the invasive tumors into subtypes (Luminal A, Luminal B Her2-, 
Luminal B Her2+, Her2+, and Triple negative)(17).  
 
Other outcomes, as consensus, time spent on screen reading and consensus, mammographic features and 
radiation doses for the two techniques were also included in the protocol, as well as interval and breast cancers in 
consecutive screening round. At least two years of follow-up of each individual woman is needed to obtain 
complete data for latter two outcomes.  
 
We defined women’s screening history as prevalent or subsequent, the former indicating the first or incident 
screen in BreastScreen Norway, and the latter indicating prior attendance in the program and the availability of 
prior screening mammograms (DM) for comparison during screen reading. 
 
Statistical analysis 
The hypothesis of our RCT was that the rate of screen-detected breast cancer would be superior for DBT versus 
DM. In a population with an estimated prior screen-detected breast cancer rate of 0.60%, we calculated that with 
15,000 women in each arm, we could observe an detection from 0.60% with DM to 0.88% with DBT, given 80% 
power and a two-sided significance threshold of 5%.  
Our analyses included information from all women with a complete screening examination, who had no prior 
history of breast cancer or metastatic melanoma, and who did not report breast symptoms when attending for 
screening examination. These women represent the per-protocol population. No women revoked their consent in 
the study. Results from interim analyses on consensus and recall rate, in addition to radiation dose for DBT 
versus DM from the first year of the recruitment period were performed as planned (15).  
Our primary goal was to estimate crude risk ratios (RR) with 95% confidence intervals (CI) for screen-detected 
breast cancer for DBT with DM as the reference, using a log-binomial regression model. Log-binomial 
regression models were also fitted to estimate the RR of recall for women screened with DBT versus DM.   
All analyses were stratified by the randomly assigned screening technique (DBT or DM). Age was categorized 
into four groups; <55, 55-59, 60-64 and ≥65 years. Consensus, recall, biopsy, and screen-detected breast cancer 
were presented as rates per 100 screened women within the recruitment period, while PPV-1 and 2 were 
presented as percentages. The distributions of histopathologic tumor characteristics were reported as percentages 
for cases with non-missing values. Tumor diameter (mm) and time spent on initial and consensus reading 
(min:sec) did not follow a perfect normal distribution, thus we estimated both mean with standard deviation 
(SD), and median values with interquartile range (IQR).  
For sensitivity analyses, we performed log-binomial regression models to estimate crude RR for screen-detected 




We used STATA version 15.0 (Stata Corp, TX) for all statistical analyses and tested differences across 
categories using two-sample t-tests, chi-square tests, one-way ANOVA or tests of proportions (Z-test). A p-value 
of <0.05 was considered statistically significant. 
 
Role of funding source 
The funder of the study had no role in the study design, data collection, analyses, interpretation, or writing of the 
report. SH, ÅH, and SS had full access to all the data in the study, and the corresponding author (SH) had final 
responsibility for the decision to submit the manuscript. 
 
Results  
Among the 44,266 women invited to the screening unit in Bergen during the recruitment period, Jan 15, 2016 – 
Dec 31, 2017, 32,976 (74.5 %) attended (Figure 1). Non-consenting women (9.1 %, 2999/32,976) and those with 
breast implants (1.6%, 524/32,976) were not included in the trial, leaving 29,453 (89.3 %) eligible for 
randomization. Of those, 14,734 were allocated to screening with DBT and 14,719 to DM. Additional exclusions 
post-randomization (breast cancer diagnosed before date of screening, metastatic melanoma, and reporting 
symptoms of breast cancer at the screening examination) resulted in a final study population of 28,749 women; 
14, 380 randomly assigned to DBT and 14,369 to DM during the recruitment period (Figure 1). Baseline 
characteristics for the study group are presented in Table 1 while characteristics prior to post-randomization 
exclusions are available in Appendix B. 
The number of women diagnosed with screen-detected breast cancer due to mammographic findings was 182; 31 
DCIS and 151 invasive cancers (Table 2). Four women were diagnosed with bilateral cancer (n=2 for DBT and 
n=2 for DM). The rate of screen-detected breast cancer did not differ between DBT and DM 0.66 % (95/14,380) 
versus 0.61 % (87/14,369, p=0.56), respectively. The risk ratio of screen-detected breast cancer did not differ 
between the two techniques (RR=1.09, 95 % CI: 0.82-1.46, p=0.56), while the risk of recall was lower for DBT 
versus DM (RR=0.78, 95 % CI: 0.69-0.88, p<0.0001). Summary of outcomes, without any post-randomization 
exclusions, are available in Appendix C.  
Consensus was 6.3 % (908/14,380) for DBT and 7.4 % (1060/14,369) for DM (p=0.0004) (Table 2). Recall was 
3.1 % (444/14,380) for DBT and 4.0 % (571/14,369) for DM (p<0.0001). The biopsy rate did not differ between 
DBT and DM (1.8% (252/14,380) versus 1.9 % (271/14,369), p=0.40, respectively). PPV-1 was statistically 
higher for DBT (21.4 %; 95/444) compared to DM (15.2 %; 87/571, p=0.01), while PPV-2 was not (p=0.18). RR 
for recall and screen-detected breast cancer without any post-randomization exclusions and  results of sensitivity 
analyses, stratified by screening history are available in Appendix D and E, respectively.  
Consensus, recall and detection increased during the study period for DBT (p=0.02, 0.01, and 0.04, respectively) 
(Figure 2a, b and c). For DM, an increase was observed for recall (p=0.01).  
The distribution of histopathological tumor characteristics did not differ statistically between the two arms of the 
RCT for invasive breast cancer (Table 3), or for DCIS (Table 4).  
All eight radiologists read both DBT and DM during the trial, ranging from 1079 to 5663 examinations for DBT 
and from 1067 to 7538 for DM, per radiologist (Appendix F). Overall, mean time spent on initial screen reading 
was 01:06 (median 00:48, IQR: 00:45) for DBT, including interpretation of SM and DBT planes as well as 
priors, and 00:39 (median 00:23, IQR: 00:31) for DM, including interpretation of priors (p for difference in 
reader time between DBT and DM: <0.0001). Mean time for each radiologist ranged from 00:39 to 02:42 for 
DBT and from 00:13 to 03:02 for DM. Mean time spent on consensus was 02:51 with SD 01:48 (median: 02:21, 
IQR:01:50) for DBT and 02:04 with SD 02:05 (median: 01:42, IQR: 1:11) for DM (p<0.0001), respectively 
(Appendix G).  
 
Discussion 
This large-scale RCT compared results from screening with DBT including SM, with standard DM, in an 
organized population-based breast cancer screening program. The breast cancer detection did not differ 
statistically significantly for women screened with DBT versus DM. We observed lower consensus and recall for 
women screened with DBT versus DM, while the PPV for recalls was higher for DBT compared to DM. The 
distribution of histopathologic tumor characteristics did not differ statistically significantly between the two 
screening techniques. 
Our finding of no statistical difference in breast cancer detection for DBT versus DM was inconsistent with 
results from the majority of both paired and unpaired studies (1). Our intervention arm used DBT+SM, whereas 
most of the others studies have used DBT+DM. A similar effect of SM and DM in combination with DBT has 
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been consistently reported (3, 18-20), however, the quality of SM may present differently for different DBT 
machines and software versions. 
It is commonly assumed that DM is superior to DBT in the characterization of microcalcifications. However, 
recent studies have shown that the perceptibility of microcalcifications is also adequate for DBT in combination 
with SM (21, 22). Several factors influence image quality of both DBT, including SM, and DM, such as 
filter/anode combinations, spatial resolution, the angular range of the x-ray tube and radiation dose (21, 23). It 
could be argued that the radiation dose measured for DBT in our study, which was lower than that reported in 
other studies of DBT (15), may have negatively affected the image quality. However, differences in vendor-
specific technical implementations and the optimization of mammography workstations can also affect image 
quality. Moreover, different requirements for training to start screen reading, reading conditions and protocols, 
including the availability and use of prior mammograms, could have influenced the radiologists’ perception and 
interpretation of mammographic features, and thus contributed to the heterogeneity of results in the published 
literature to date.  
We used two-view mammography with independent double-reading and separate consensus in both trial arms 
and a hanging protocol with availability of screening and any diagnostic mammograms taken during the previous 
ten years, in line with standard procedues. However, the radiologists’ experience in DM screen reading prior the 
start of the trial varied, and the program’s recommendations of 5000 annual screen readings was met by half of 
the radiologists (15). Further, reading volume varied between radiologists for DBT and DM during the trial. It 
has been claimed that experience in screen reading and preferences of DM or DBT might influence reader 
sensitivity (24, 25). Radiologists in this study were not exposed to any preliminary results during any part of the 
trial, which we consider a strength; this made it impossible to provide individual feedback about their 
performance. Nonetheless, the radiologists were involved in both screen reading and recall assessments and thus 
not blinded to the final outcome of the women’s screening examination.  
All participating radiologists were somewhat trained in DBT screen reading and diagnostics prior to the start of 
the trial, but they did not practice it in an everyday screening setting until the trial started (15). A lack of 
experience in screen reading of DBT is therefore considered a limitation of our study (26) and it is possible that 
the radiologists had not yet achieved optimal screen reading capabilities with DBT at the start-up of the trial.  
Despite this potential limitation, time used for screen reading was lower in the To-Be trial than reported from the 
Oslo Tomosynthesis Screening Trial, 66 seconds for DBT and 39 seconds for DM in our study, compared with 
91 seconds for DBT+DM and 45 seconds for DM alone in the Oslo trial (4). This could represent cultural 
differences between the two breast centers, although our results showed substantial variation in time used for 
screen reading between the radiologists.  
Analysis of the radiologist’s sensitivity, interval and consecutive round screen-detected breast cancer, and 
reviews of cases dismissed at consensus, interval and next round screen-detected breast cancers are needed to 
conclude whether the cancer cases were missed due to interpretation errors. Admittedly, consensus, recall and 
detection increased over the two years recruitment period for DBT, while an increase was observed only for 
recalls for DM. These findings might represent a learning effect for DBT. The increase in recall for DM might 
represent natural variation, or study effect.  
The availability of prior screening and diagnostic images at screen reading might have influenced the number of 
cases discussed at consensus, and cases dismissed at consensus. It is possible that findings on DBT images were 
present and perceptible by radiologists on the prior DM, but considered non-suspicious and interpreted as 
negative, or positive but dismissed on the consensus. Lack of obvious findings on the current SM and/or the 
slabs and planes might have downgraded their interpretation or dismissed cases at consensus (27). Furthermore, 
the availability of several sets of prior mammograms could have been distracting instead of elucidative to the 
radiologists. These factors might have influenced the rates of recall and breast cancer detection, as well as the 
histopathological tumor characteristics in the DBT arm. We presume that calling women with these findings 
back for further assessment might have led to a higher detection of breast cancer in our study, however, we do 
not know whether these lesions represent small tumors of low histologic grade or “killing cancers”.  
Our results on histopathologic tumor characteristics are in line with those from the Malmö tomosynthesis trial 
(5). The distribution of tumor diameter, histologic grade and tumor cell proliferation index by Ki67 staining 
indicated an increase in the detection of node-negative progressive tumors, which could be considered favorable 
for DBT. The relatively high number of cases with no available tumor diameter may have affected the mean 
tumor diameter in our study and is likely related to new guidelines that recommend neoadjuvant treatment for 
some tumors ≥20 mm (28). Our histopathologic findings diverge somewhat from some of the other studies, 




To investigate a possible study effect, we compared recall in Bergen prior to the trial, 2008-2015, with results 
from the trial. The recall prior to the trial was 3.3%, which did not differ from the recall for DBT (3.1%, p=0.18), 
in contrast to the recall for DM which was higher (4.0%, p<0.0001). The change in recall in Bergen is likely a 
study effect and is expected to affect both arms equally. However, our study was designed to compare results of 
DBT versus DM regardless of this underlying effect. Recall for Norway, Bergen excluded, was 2.9% in the pre-
trial period, while it increased to 3.3% during the trial period, which indicate a higher recall in Bergen than the 
rest of Norway, irrespective of the trial. The breast cancer detection in our trial did not differ from the pre-trial 
period (0.62%), either for DBT (0.66%, p=0.60) or for DM (0.61%, p=0.79). Similar comparison for 
BreastScreen Norway, Bergen excluded, showed a screen-detected breast cancer of 0.55% in the pre-trial period 
and 0.59% in the trial period. The pre-trial rates did not differ statistically from the rates shown in the trial in 
either Bergen or in Norway. These comparisons are not consistent with a possible study effect on the primary 
outcome of the trial. 
Despite several studies demonstrating a higher rate of screen-detected breast cancer with DBT than DM, the 
implementation of DBT in population-based screening programs has been anything but rapid. This could be due 
to lack of evidence from studies with sufficiently large study samples and robust study designs, as well as the 
problematic finding of an increased incidence of small, low histologic grade tumors without a corresponding 
decrease in the rate of interval breast cancers. Given the results described above regarding rates of screen-
detected breast cancer for DBT, and since our trial is one of the earliest program-embedded RCTs of DBT 
screening, we present a reflection on factors that might have shaped our study findings in order to inform future 
breast cancer screening research. 
Running a RCT of new technology in an everyday screening setting is a challenging task, which the To-Be trial 
managed proficiently by masking interim results, using a closed pool of radiographers and radiologists, and by 
using standardized imaging, screen reading and consensus procedures in both arms; our findings therefore reflect 
real-world screening outcomes for a RCT.  
The population-based RCT design, a high participation rate, and a high level of data completeness due to linkage 
with the Cancer Registry of Norway are all strengths of the To-Be trial. However, there are some limitations to 
our trial. First, our assumed rate of screen-detected breast cancer in the DBT arm (based on current knowledge at 
study inception) was somewhat exaggerated, leading to diminished statistical power. In retrospect, a combination 
of a superiority and non-inferiority RCT might have been a better design (30), given the observed detection rate 
and the final study sample size. For the observed breast cancer rates, we would have needed about 400,000 
women in each arm to detect statistically significant difference.  
Increasing the sample size in our RCT would have been difficult, as an extension of study period would have 
resulted in the inclusion of women with DBT as a prior screening exam, instead of increasing the sample size of 
women first time screened with DBT. Since we included all women who attended the screening unit in Bergen 
during the recruitment period, a multicenter study would be the only way to increase the study population.  
Another limitation is that the To-Be trial is a single-center trial using equipment from one vendor. Our results 
may therefore have limited generalizability to other settings. Additionally, we do not currently have sufficiently 
long follow-up period to report on interval breast cancers or breast cancer mortality. A longer follow-up time is 
also needed for analyses on patient reported outcome measures, which is on our long-term plan. Further, we 
expect to stratify our findings by mammographic density in later analyses.  
Lastly, although we did several analyses, we tested and found that employing a statistical correction for multiple 
testing, such as the Bonferroni correction would not alter our conclusions. 
In summary, our population-based breast cancer screening RCT using first generation DBT with SM versus DM 
alone did not identify a statistical difference in the rate of screen-detected breast cancer.The distribution of 
histopathologic tumor characteristics did not differ between the two arms either. A lower recall rate and a higher 
positive predictive value for recall was found for women screened with DBT compared to those screened with 
DM. Our results indicate that use of DBT in a screening setting is safe for women at average risk of breast 
cancer. Further studies with longer follow-up that analyze interval and screen-detected breast cancer in the 
consecutive screening round are needed to better understand the effect of DBT in a population-based screening 
setting.  
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Figure legends 
Figure 1: Study population in the To-Be trial  
Figure 2: Consensus (upper panel), recall (middle panel) and screen-detected breast cancer (SDC, lower panel) 
per 100 women screened, by time since start-up of the To-Be trial, and screening technique (DBT and DM). 
Tested for trend with one-way ANOVA. 
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Research in Context 
Evidence before this study 
Two of the investigators (SH and NH) undertook a literature search (MEDLINE: 2010 to August 2015; 
explorded ‘breast neoplasms’ and searched ‘tomosyn$’ in the title) to identify studies reporting screening 
outcomes for population-based breast screening with digital breast tomosynthesis (DBT): there were no RCTs of 
DBT screening. Three prospective non-randomized trials and several retrospective studies reported screening 
performance measures for DBT, predominantly in combination with standard digital mammography (DM). This 
indicated that DBT+DM generally improved screening outcome measures by increasing cancer detection and/or 
reducing recall compared to DM alone, although effect estimates varied. Only two of these studies investigated 
screen reading using DBT alone, or investigated DBT including synthetic 2D mammograms (SM) (as one of the 
screen reading strategies. Both studies were prospective and reported only interim analyses. The former showed 
that DBT alone significantly increased cancer detection and recall rate, while the latter showed equivalence in 
cancer detection between DBT+SM and DBT+DM.  
Added value of this study 
To our knowledge, this is the first RCT reporting outcomes for screening with DBT+SM in a high-throughput, 
population-based breast cancer screening program. In contrast to the majority of other studies, we did not find 
statistically significant differences in breast cancer detection rates or tumor characteristics for DBT+SM versus 
DM alone. We found a lower recall rate and higher positive predictive value of recalls among those screened 
with DBT compared to DM. Our results indicate that DBT+SM is as good a screening tool as standard DM for 
selected breast cancer screening outcome measures in a population based screening program for women at 
average risk of breast cancer. These results will be valuable in the coming policy discussions about whether to 
implement DBT in breast cancer screening programs.  
Implication of all the available evidence 
The evidence on DBT as a screening tool points towards a higher rate of screen-detected breast cancer and 
prognostically favorable tumor characteristics among women screened with DBT in combination with DM or 
SM, compared with standard DM. In our study, we compared outcome measures for DBT+SM versus standard 
DM in a modern screening program, BreastScreen Norway, which offers women aged 50-69 biennial 
mammography screening, and independent double reading with consensus. Results from our real-world, 
screening-based RCT using DBT+SM as the intervention, will inform upcoming policy decisions about 
implementing DBT in an organized, population-based screening program for breast cancer. Our results indicate 
that use of DBT in a screening setting is safe, and has the potential to reduce harms associated with 
mammographic screening. Further studies on interval and screen-detected breast cancer in consecutive screening 
rounds are needed to better understand the effect of DBT in a population-based screening setting. Additionally, 
more knowledge is needed about the recommendations and, ultimately, the requirements for radiologists to start 
screen reading with DBT, as well as the economic aspects of implementing DBT in a screening setting. These 
knowledge gaps should be filled, and our results should be replicated in other national screening programs, in 
order to make an evidence-based decision regarding whether DBT should replace DM as the standard tool for 
breast cancer screening. 
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Table 1: Baseline 
characteristics of 
the women 









Table 2: Summary of outcomes in the To-Be trial 
  Screening technique   
 
Total DBT DM p-value
¥ 
 
n = 28,749 n = 14,380 n = 14,369 
 
n % (95% CI) n % (95% CI) n % (95% CI) 
 
SDC# 182 0.63  (0.54-0.73) 95 0.66 (0.53-0.79) 87 0.61 (0.48-0.73) 0.56 
DCIS¤ 31 0.11  (0.07-0.15) 15 0.10 (0.05-0.16) 16 0.11 (0.06-0.17) 0.86 
Invasive  151 0.53  (0.44-0.62) 80 0.56 (0.43-0.68) 71 0.49 (0.38-0.61) 0.47 
Recall 1015 3.5  (3.3-3.8) 444 3.1 (2.8-3.4) 571 4.0 (3.7-4.3) <0.0001 
PPV-1  17.9  (15.6-20.4)  21.4 (17.6-25.2)  15.2 (12.3-18.2) 0.01 
PPV-2  34.8  (30.7-39.1)  37.7 (31.7-43.7)  32.1 (26.5-37.7) 0.18 
Biopsy 523 1.8  (1.7-2.0) 252 1.8 (1.5-2.0)  271 1.9 (1.7-2.1) 0.40 
Consensus 1968 6.8  (6.6-7.1) 908 6.3  (5.9-6.7) 1060 7.4 (6.9-7.8) 0.0004 
#SDC: Screen-detected breast cancer 
¤DCIS: Ductal Carcinoma In Situ 
¥ p-value for Z-test between DBT and DM 
 
  
  Screening technique 
  Total DBT DM 
 
n = 28,749 n = 14,380 n = 14,369 
 
n % (95% CI) n % (95% CI) n % (95% CI) 
Age  
      <55 years 7559 26.3 (25.8-26.8) 3746 26.1 (25.3-26.8) 3813 26.5 (25.8-27.3) 
55-59 years 7296 25.4 (24.9-25.9) 3628 25.2 (24.5-25.9) 3668 25.5 (24.8-26.2) 
60-64 years 7117 24.8 (24.3-25.3) 3625 25.2 (24.5-25.9) 3492 24.3 (23.6-25.0) 
>64 years 6777 23.6 (23.1-24.1) 3381 23.5(22.8-24.2) 3396 23.6 (22.9-24.3) 
Screening history 
      Prevalent 4066 14.1 (13.7-14.6) 2013 14.0 (13.4-14.6) 2053 14.3 (13.7-14.9) 
Subsequent  24,683 85.9 (85.4-86.3) 12,367 86.0 (85.4-86.6) 12,316 85.7 (85.1-86.3) 
Table
Table 3: Histopathologic tumor characteristics of invasive screen-detected breast cancer  
  Total DBT DM 
p-value  n = 151 n = 80 n = 71 
 n % (95% CI) n % (95% CI) n % (95% CI) 
Histologic type 
       Carcinoma NST 113 74.8 (67.1-81.5) 62 77.5 (66.8-86.1) 51 71.8 (59.9-81.9) 0.11¥ 
Lobular carcinoma 19 12.6 (7.7-19.0) 6 7.5 (2.8-15.6) 13 18.3 (10.1-29.3) 
 Tubular carcinoma 6 4.0 (1.5-8.4) 2 2.5 (0.3-8.7) 4 5.6 (1.6-13.8) 
 Other carcinoma¤ 13 8.6 (4.7-14.3) 10 12.5 (6.2-21.8) 3 4.2 (0.9-11.9) 
 Tumor diameter§ 
       Mean, SD (mm) 130 15.3, 8.5 70 16.0, 8.4 60 14.5, 8.8 0.33€ 
Median, IQR (mm) 130 14.0, 8.6 70 14.9, 7.0 60 14.0, 10.3  
        
<10 mm 28 21.5 (14.8-29.6) 10 14.3 (7.1-24.7) 18 30.0  (18.8-43.2) 0.09¥ 
≥10-<20 mm 72 55.4 (46.4-64.1) 43 61.4 (49.0-72.8) 29 48.3 (35.2-61.6) 
 ≥20 mm 30 23.1  (16.1-31.3) 17 24.3 (14.8-36.0) 13 21.7 (12.1-34.2) 





  Lymph node positive 32 21.5 (15.2-28.9) 14 17.7 (10.0-27.9) 18 25.7 (16.0-37.6) 0.24¥ 





  Histologic grade 
       1 46 31.7 (24.3-40.0) 22 28.9 (19.1-40.5) 24 34.8 (23.7-47.2) 0.53¥ 
2 73 50.3 (41.9-58.7) 38 50.0 (38.3-61.7) 35 50.7 (38.4-63.0) 
 3 26 17.9 (12.1-25.2) 16 21.1 (12.5-31.9) 10 14.5 (7.2-25.0) 





  ER+ 140 93.3 (88.1-96.8) 71 89.9 (81.0-95.5) 69 97.2 (90.2-99.7) 0.07¥ 





  PR+ 123 82.0 (74.9-87.8) 61 77.2 (66.4-85.9) 62 87.3 (77.3-94.0) 0.11¥ 





  Her2+ 16 10.7 (6.2-16.7) 8 10.1 (4.5-19.0) 8 11.3 (5.0-21.0) 0.82¥ 





  Ki67 ≥30% 34 25.0 (18.0-33.1) 21 29.6 (19.3-41.6) 13 20.0 (11.1-31.8) 0.20¥ 





  Subtype 
       Luminal A 87 60.0 (51.5-68.0) 44 58.7 (46.7-69.9) 43 61.4 (49.0-72.8) 0.43¥ 
Luminal B Her2- 36 24.8 (18.0-32.7) 18 24.0 (14.9-35.3) 18 25.7 (16.0-37.6) 
 Luminal B Her2+ 12 8.3 (4.3-14.0) 5 6.7 (2.2-14.9) 7 10.0  (4.1-19.5) 
 Her2+ 4 2.8 (0.8-6.9) 3 4.0 (0.8-11.2) 1 1.4 (0.04-7.7) 
 Triple Negative 6 4.1 (1.5-8.8) 5 6.7 (2.2-14.9) 1 1.4 (0.04-7.7) 
    Information not available 6   5   1     
¤ Including mucinous and other invasive cancers 
§ Neo-adjuvant treated women had no information available about tumor diameter 
¥ p-value for Chi-square test between DBT and DM 
€ p-value for t-test of mean tumor diameter, between DBT and DM 
 
Table 4: Histopathologic tumor characteristics of screen-detected ductal carcinoma in situ 
 
   Total DBT DM 
p-value 
 
n = 31 n = 15 n = 16 
 
n % (95% CI) n % (95% CI) n % (95% CI) 
Tumor diameter 
       Mean, SD (mm) 29 27.6, 25.9 13 26.4, 15.7 16 28.5, 32.5 0.83€   
Median, IQR (mm) 29 23.0, 18.0 13 28.0, 10.0 16 18.5, 25.3  
        
<20 mm 11 37.9 (20.7-57.7) 3 23.1 (5.0-53.8) 8 50.0 (24.7-75.3) 0.14¥ 
≥20 mm 18 62.1 (42.3-79.3) 10 76.9 (46.2-95.0) 8 50.0 (24.7-75.3) 





  Grade 
       1 3 10.0 (2.1-26.5) 2 13.3 (1.7-40.5) 1 6.7 (0.2-31.9) 0.82¥ 
2 10 33.3 (17.3-52.8) 5 33.3 (11.8-61.6) 5 33.3 (11.8-61.6) 
 3 17 56.7 (37.4-74.5) 8 53.3 (26.6-78.7) 9 60.0 (32.3-83.7) 
     Information not available 1   0   1     
¥ p-value for Chi-square test  between DBT and DM 
€  p-value for t-test of mean tumor diameter between DBT and DM 
The Tomosynthesis trial in Bergen – the To-Be trial 
All women invited to mammographic screening in BreastScreen Norway in Bergen, Hordaland,  
2016-2017 
 n = 44,266 
Women attending screening in Bergen 
n = 32,976 (74.5%) 
Women invited and consenting to participate in 
the To-Be trial 
 
n = 29,453 (89.3% of the attending women) 
DBT 
n = 14,734 (50.0%) 
Women invited, but not consenting to 
participate in the To-Be trial (n = 2999)  
Women with implants (n = 524) 
n = 3523 (10.7% of the attending women) 
 
DM 
n = 14,719 (50.0%) 
Excluded:  
Prior breast cancer: 
n = 314 
Recalled due to 
symptoms:  
n = 39 
Metastasis from 
melanoma: 
n = 1 
 
Consensus: n = 908 
Recall: n = 444 
Biopsy: n = 252 
SDC: n = 95 
(+2 bilateral  n = 97)  
 
Consensus: n = 1060 
Recall: n = 571 
Biopsy: n = 271 
SDC: n = 87 
(+2 bilateral  n = 89) 
Randomization 
Excluded:  
Prior breast cancer: 
n = 316 
Recalled due to 
symptoms:  
n = 34 
DBT 
n = 14,380 (50.0%) 
DM 
n = 14,369 (50.0%) 
















































































































































































The Tomosynthesis study in Bergen – the To-be trial 
Approved by the Regional Committees for Medical and Health Research Ethics in the South East of Norway 
(official record number 2015/424) and registered at ClinicalTrials.gov (NCT02835625) 




Study title Digital breast tomosynthesis – the future screening tool for breast cancer? 
Study phase Data will be collected from a two year recruitment period (2016 and 
2017) and for two years after the recruitment period, for estimation of 
interval and breast cancer in consecutive screening round 
Background Digital breast tomosynthesis (DBT) is an advancement of mammography, 
and has the potential to overcome limitations of standard digital 
mammography (DM). The use of DBT+DM roughly doubles the radiation 
dose compared to DM alone. As a result, synthetic 2D mammograms (SM) 
was developed using raw-data from the DBT acquisition to minimize the 
radiation burden to women. As of yet, there is insufficient evidence to 
draw any conclusions about the overall balance of benefits and harms of 
using DBT+SM in a population-based screening program. 
Study aim To investigate the potential superiority of first generation DBT+SM versus 
DM in an organized population-based screening program 
Study setting The breast center at Haukeland University hospital, as a part of the 
national screening program, BreastScreen Norway 
Study design A large-scale, parallel group, superiority RCT 
Outcome measures Primary outcome:  
Screen-detected breast cancer  
Secondary outcomes: 
Recalls, positive predictive value of recalls and biopsies, prognostic and 
predictive tumor characteristics, economical aspects  
Other Outcome Measures: 
Consensus, time spent on screen-reading and consensus, mammographic 
features, radiation doses and other early performance measures 
After two years of follow up for the individual women:  
Interval cancer and screen-detected breast cancer among consecutively 
screened women  
Study population The target group is 45 000 women aged 50-69. We expect 75% 
attendance rate in the program, and 90% participation rate in the trial, 
resulting in 30 000 women in total, 15 000 in each arm 
Inclusion/exclusion 
criteria 
Inclusion criteria: Women who attend BreastScreen Norway with a 
complete screening exam and signed an informed consent 
 
Exclusion criteria: Women with breast implants were not considered for 
participation in the trial. Women who have prior history of breast cancer 
*Protocol
or metastatic melanoma, or who report breast symptoms when attending 
for screening examination will be screened as usual, but excluded post-
randomization. 
Randomization Fully concealed, simple randomization and 1:1 allocation ratio. The 
intervention will not be blinded 
Procedures Screening with two-view DBT+SM or two-view standard DM. Independent 
double reading of the screening mammograms, by a pool of eight breast 
radiologists. All cases with a positive score will be discussed at a 
consensus meeting where the decision of whether to recall the women 
for further assessment will be taken  
Assessments Women recalled will undergo further assessment, such as additional 
imaging and needle biopsy  
Sample size calculation In a population with an estimated screen-detected breast cancer rate of 
0.60%, we calculated that with 15,000 women in each arm, we could 
observe an increase in prevalence from about 0.60% with DM to 0.88% 
with DBT, with 80% power using a two-sided significance threshold of 5%  
Statistical analysis Variables will be described and tested using chi squared tests, t-tests, one 
way ANOVA and Z tests. The primary outcome will be analyzed with a log-
binomial regression model and presented as crude risk ratios with a 95 % 
confidence interval 
Safety considerations In addition to adhering to the ethical approvals obtained, an interim 
analysis will be performed after 1 year and published in a peer-reviewed 
journal to control radiation dose and selected early performance 
measures 
Project management Consortium: 
Haukeland University Hospital 
Cancer Registry of Norway 
University of Oslo 
 
The consortium appoints a Steering Committee. The project group will be 
led by PI Solveig Hofvind. 
Study sponsor The Norwegian Research Council 
 
